JOHNSON & JOHNSON's ticker is JNJ and the CUSIP is 478160104. A total of 1,956 filers reported holding JOHNSON & JOHNSON in Q4 2013. The put-call ratio across all filers is 1.69 and the average weighting 1.4%.
About JOHNSON & JOHNSON
Johnson & Johnson is a multinational corporation that specializes in the production of medical devices, pharmaceuticals, and consumer goods. The company was founded in 1886 and has since become a household name in the healthcare industry. With a market capitalization of over $400 billion, Johnson & Johnson is one of the largest healthcare companies in the world.
The company's success can be attributed to its commitment to innovation and quality. Johnson & Johnson invests heavily in research and development, with a focus on developing new treatments for a variety of medical conditions. The company's pharmaceutical division is responsible for the development of many life-saving drugs, including treatments for cancer, HIV, and diabetes.
In addition to its pharmaceuticals, Johnson & Johnson is also known for its consumer goods. The company produces a wide range of products, including baby care items, skincare products, and over-the-counter medications. Many of these products are household names, such as Band-Aid, Tylenol, and Neutrogena.
Despite its success, Johnson & Johnson has faced its fair share of challenges. In recent years, the company has been involved in several high-profile lawsuits related to the safety of its products. However, the company has taken steps to address these issues and remains committed to providing safe and effective products to its customers.
Overall, Johnson & Johnson is a company that has made significant contributions to the healthcare industry. With its focus on innovation and quality, the company is well-positioned to continue its success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $110,186 | -11.1% | 753,873 | -3.7% | 0.19% | -13.4% |
| Q1 2024 | $123,901 | +5.4% | 783,238 | +4.4% | 0.22% | -2.2% |
| Q4 2023 | $117,544 | -10.3% | 749,937 | -10.9% | 0.23% | -20.5% |
| Q3 2023 | $131,072 | +18.2% | 841,549 | +25.6% | 0.29% | +22.6% |
| Q2 2023 | $110,926 | +182.2% | 670,167 | +164.3% | 0.24% | +152.7% |
| Q1 2023 | $39,303 | -15.6% | 253,571 | -3.8% | 0.09% | -17.7% |
| Q4 2022 | $46,566 | -99.9% | 263,602 | -3.4% | 0.11% | -2.6% |
| Q3 2022 | $44,569,000 | -8.7% | 272,821 | -0.8% | 0.12% | -4.9% |
| Q2 2022 | $48,801,000 | -9.2% | 274,921 | -9.3% | 0.12% | +8.0% |
| Q1 2022 | $53,734,000 | -12.0% | 303,189 | -15.1% | 0.11% | -7.4% |
| Q4 2021 | $61,085,000 | +33.7% | 357,085 | +26.3% | 0.12% | +25.8% |
| Q3 2021 | $45,678,000 | +26.0% | 282,834 | +28.5% | 0.10% | +22.8% |
| Q2 2021 | $36,250,000 | +2.3% | 220,049 | +2.1% | 0.08% | -7.1% |
| Q1 2021 | $35,432,000 | +8.9% | 215,591 | +4.3% | 0.08% | -1.2% |
| Q4 2020 | $32,529,000 | -12.5% | 206,687 | -17.3% | 0.09% | -21.8% |
| Q3 2020 | $37,194,000 | -1.5% | 249,831 | -7.0% | 0.11% | -7.6% |
| Q2 2020 | $37,769,000 | +18.3% | 268,577 | +10.3% | 0.12% | -7.8% |
| Q1 2020 | $31,929,000 | +12.6% | 243,480 | +25.3% | 0.13% | +40.2% |
| Q4 2019 | $28,354,000 | +21.1% | 194,383 | +7.4% | 0.09% | +9.5% |
| Q3 2019 | $23,417,000 | -0.7% | 180,986 | +6.9% | 0.08% | +6.3% |
| Q2 2019 | $23,576,000 | -4.8% | 169,271 | -4.5% | 0.08% | -16.8% |
| Q1 2019 | $24,774,000 | -6.0% | 177,226 | -13.3% | 0.10% | -17.4% |
| Q4 2018 | $26,368,000 | -89.0% | 204,326 | -88.2% | 0.12% | -87.1% |
| Q3 2018 | $238,714,000 | -1.9% | 1,727,672 | -13.8% | 0.89% | -5.8% |
| Q2 2018 | $243,329,000 | +1.7% | 2,005,348 | +7.4% | 0.94% | +1.4% |
| Q1 2018 | $239,295,000 | -5.6% | 1,867,297 | +2.9% | 0.93% | -5.4% |
| Q4 2017 | $253,596,000 | +3.6% | 1,815,032 | -3.6% | 0.98% | +0.7% |
| Q3 2017 | $244,861,000 | -13.4% | 1,883,397 | -11.9% | 0.98% | -14.3% |
| Q2 2017 | $282,828,000 | +7.2% | 2,137,947 | +0.9% | 1.14% | +3.6% |
| Q1 2017 | $263,791,000 | +136.8% | 2,117,958 | +119.1% | 1.10% | +114.4% |
| Q4 2016 | $111,387,000 | +27.4% | 966,806 | +30.6% | 0.51% | +16.6% |
| Q3 2016 | $87,435,000 | -21.4% | 740,160 | -19.3% | 0.44% | -27.9% |
| Q2 2016 | $111,284,000 | +37.4% | 917,439 | +22.6% | 0.61% | +33.5% |
| Q1 2016 | $80,994,000 | +86.6% | 748,552 | +77.1% | 0.46% | +88.8% |
| Q4 2015 | $43,414,000 | +13.9% | 422,639 | +3.5% | 0.24% | +11.0% |
| Q3 2015 | $38,119,000 | -85.1% | 408,345 | -84.5% | 0.22% | -83.7% |
| Q2 2015 | $256,000,000 | -10.8% | 2,626,721 | -7.9% | 1.34% | -8.1% |
| Q1 2015 | $286,975,000 | +8.9% | 2,852,647 | +13.2% | 1.46% | +2.5% |
| Q4 2014 | $263,474,000 | -38.6% | 2,519,595 | -37.4% | 1.42% | +10.6% |
| Q3 2014 | $429,016,000 | +731.8% | 4,024,924 | +716.4% | 1.28% | +304.7% |
| Q2 2014 | $51,576,000 | +10.4% | 492,981 | +3.6% | 0.32% | +0.6% |
| Q1 2014 | $46,728,000 | +2.7% | 475,678 | -4.2% | 0.32% | -3.4% |
| Q4 2013 | $45,488,000 | +11.3% | 496,558 | +5.3% | 0.33% | -1.8% |
| Q3 2013 | $40,873,000 | +60.7% | 471,521 | +59.2% | 0.33% | +45.6% |
| Q2 2013 | $25,438,000 | – | 296,271 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ROBERT WOOD JOHNSON FOUNDATION | 13,000,000 | $1,360,060,000 | 100.00% |
| Pettee Investors, Inc. | 159,896 | $16,728,000 | 15.21% |
| CINCINNATI INDEMNITY CO | 25,000 | $2,616,000 | 11.85% |
| West Coast Asset Management | 58,032 | $6,071,351,000 | 10.68% |
| ARMSTRONG HENRY H ASSOCIATES INC | 421,310 | $44,077,000 | 10.51% |
| ACR Alpine Capital Research, LLC | 630,494 | $65,962,000 | 10.09% |
| Tweedy, Browne Co LLC | 4,196,224 | $439,009,000 | 9.38% |
| Barbara Oil Co. | 102,000 | $10,671,000 | 9.08% |
| GREEN VALLEY INVESTORS LLC | 3,625,000 | $379,249,000 | 8.82% |
| Independent Franchise Partners LLP | 5,027,026 | $525,927,000 | 8.01% |